Original GlobalRPh source
- Product / population
- Preserved GlobalRPh source, not a freshly verified product label
- Renal measure
- Use the method specified in the original source
- Source revision
- Historical source; revision not established here
- Retrieved
- 2026-09-05 (not the revision date)
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
These historical serum-creatinine cutoffs are not a current-label validation. A separately attributed current U.S. eGFR-based label must control current product-label dosing.
The preserved source uses historical serum-creatinine cutoffs. The imported U.S. immediate-release label instead uses indexed eGFR, and contraindicates use below 30 mL/min/1.73 m2. The old rule and current-label summary must not be blended.
Usual Dosing (Adults)
Immediate-release: start 500 mg twice daily or 850 mg daily; increase by 500 mg weekly or 850 mg every 2 weeks to 2,000 mg/day in divided doses; maximum 2,550 mg/day. Glucophage XR: start 500 mg with the evening meal; increase by 500 mg weekly to a maximum 2,000 mg with the evening meal.
Renal Dosing
The historical source lists contraindications at serum creatinine above 1.5 mg/dL in males or above 1.4 mg/dL in females, or abnormal creatinine clearance (approximately below 60-70 mL/min).
Hemodialysis
Contraindicated in the source.
